Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

KalVista Pharmaceuticals (KALV) Depreciation & Amortization (CF) (2016 - 2025)

Historic Depreciation & Amortization (CF) for KalVista Pharmaceuticals (KALV) over the last 10 years, with Q2 2025 value amounting to $261000.0.

  • KalVista Pharmaceuticals' Depreciation & Amortization (CF) rose 1917.81% to $261000.0 in Q2 2025 from the same period last year, while for Apr 2025 it was $712000.0, marking a year-over-year decrease of 1274.51%. This contributed to the annual value of $941000.0 for FY2025, which is 1531.86% up from last year.
  • KalVista Pharmaceuticals' Depreciation & Amortization (CF) amounted to $261000.0 in Q2 2025, which was up 1917.81% from $227000.0 recorded in Q4 2024.
  • In the past 5 years, KalVista Pharmaceuticals' Depreciation & Amortization (CF) ranged from a high of $261000.0 in Q2 2025 and a low of $193000.0 during Q3 2023
  • For the 3-year period, KalVista Pharmaceuticals' Depreciation & Amortization (CF) averaged around $218285.7, with its median value being $219000.0 (2024).
  • As far as peak fluctuations go, KalVista Pharmaceuticals' Depreciation & Amortization (CF) surged by 1522.84% in 2024, and later skyrocketed by 1917.81% in 2025.
  • KalVista Pharmaceuticals' Depreciation & Amortization (CF) (Quarter) stood at $197000.0 in 2023, then increased by 15.23% to $227000.0 in 2024, then increased by 14.98% to $261000.0 in 2025.
  • Its last three reported values are $261000.0 in Q2 2025, $227000.0 for Q4 2024, and $224000.0 during Q3 2024.